self injection semaglutide .25mg Stomach paralysis is the rare

This warning applies if someone has a personal or family history of medullary thyroid carcinoma or MEN-2

Novo Nordisk is the pharmaceutical titan behind Wegovy and other glucagon-like peptide-1 receptor agonists approved for type 2 diabetes and weight loss

They are generally considered for young people with obesity, which is associated with increased risks of health problems like type 2 diabetes, high blood pressure, and heart disease

Even a brief interruption in therapy can affect glucose control, so planning the overlap or gap period is critical

Researchers havent fully established exactly why Wegovy causes fatigue, as this specific side effect hasnt been extensively studied yet